[
    "{\"step_by_step_thinking\": \"Based on the provided documents, we can gather the following information: Istiratumab is an experimental monoclonal antibody that targets IGF-1R and ErbB3. It has been tested in clinical trials for the treatment of pancreatic cancer. Document [1] describes a randomized, double-blind, placebo-controlled phase II study of istiratumab plus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer. The study found that istiratumab failed to improve the efficacy of standard chemotherapy in this patient setting. Therefore, based on the available evidence, the answer is B. no, istiratumab is not effective for pancreatic cancer.\", \"answer_choice\": \"B\"}"
]